Link copied to clipboard!

Bajaj Finserv Announces Exciting Offers with Doctor Loan

IMT News Desk
IMT News Desk
· 3 min read

Bajaj Finance Limited, the lending arm of Bajaj Finserv, has announced an exciting offer for doctors who seek financing to achieve professional goals such as renovating clinics, hiring specialised staff and installing high-end equipment. Medical professionals applying for a Bajaj Finserv Doctor Loan from September 4 – November 5, 2019  stand a chance to win a trip to Abu Dhabi, a Doxper (smart pen) subscription and gift vouchers worth Rs. 5,000 while enjoying collateral-free financing of up  to Rs. 37 lakh.

This hassle-free loan offered by Bajaj Finserv is customised to fund business expansion for doctors. Here’s why medical practitioners should apply for the Business Loan for Doctors:

Win exciting rewards, including a trip to Abu Dhabi

By applying now, doctors stand to win the limited-time deals exclusively offered on Business Loan for Doctors and Personal Loan for Doctors. Doctors could also win a Doxper pen subscription, which is an ingenious solution of digitising prescriptions and patient notes, as well as gift vouchers worth Rs. 5,000. These offers are valid between September 4 – November 5, 2019.

Revamp clinics with a large, collateral-free sanction

From improving the waiting room and consultation areas and buying new hospital beds to constructing a new wing and installing state-of-the-art machines, doctors can make medium and big-ticket expenses feasible with the funding obtained from this Business Loan. Bajaj Finserv offers a large sanction, up to Rs. 37 lakh, without any collateral. With its hassle-free application process, medical professionals don’t need to carve out time from their regular, busy schedules to identify assets or undertake valuations.

Hire professionals and expand to a new location with speedy financing

This loan application requires minimal documentation. The professionals benefit from a swift 24-hour disbursal; courtesy – quick approval procedures. With instant financing at their fingertips, doctors can seize market opportunities and take impromptu decisions. Practitioners can use the sanction to set up a clinic in a new location or even upscale services by bringing speciality and super-speciality medical staff on board. Further, repayment can be made over a flexible 12 to 96-month tenor thus keeping the expenses within budget.

Ensure adequate cash flow management with the Flexi Loan facility

Working capital requirements fluctuate through the year and to ensure timely access to funds and instant liquidity, doctors can avail the Business Loan on a Flexi basis. The Flexi Loan allows customers to borrow from the sanction in parts, on the go, without needing to make fresh applications each time. Along with this benefit, the interest charges remain minimum as they apply only to the amount withdrawn and not on the entire sanction. Further, practitioners can devote more to current needs by paying interest-only EMIs through the tenor and repaying the principal at the end.

With Bajaj Finserv, Doctors can gain instant approval when they check their pre-approved loan offer and  expedite the application process.

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk